miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer
Bin Ouyang, Mingjun Bi, Mahendra Jadhao, Gregory Bick, Xiaoting Zhang, Robert-Alain Toillon, Anders M Ström · 2024
Read miR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer by Bin Ouyang, Mingjun Bi, Mahendra Jadhao, Gregory Bick, Xiaoting Zhang, Robert-Alain Toillon, Anders M Ström (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11640040.txt.
Description
Bin Ouyang and co-authors present a 2024 study on why breast cancers stop responding to tamoxifen, a standard hormone therapy. A helper protein of the estrogen receptor, MED1, is overproduced in up to sixty percent of breast cancers and predicts poor outcomes. The team hunted for what unleashes MED1 and found a tiny RNA, miR-205, that normally holds it down.
Cancer patients with high MED1 and low miR-205 fared worst, and resistant cells had lost the RNA. Restoring miR-205 in resistant cells lowered MED1 and made tamoxifen work again, in dishes and in mice. The RNA also blocks HER3, a second growth driver feeding the same pathway. The authors propose reviving miR-205 as a way to break anti-estrogen resistance.
Catalog record
| CREATOR | Bin Ouyang, Mingjun Bi, Mahendra Jadhao, Gregory Bick, Xiaoting Zhang, Robert-Alain Toillon, Anders M Ström |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |